

Stephanie Daignault

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/12099406/stephanie-daignault-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

2,534
citations

20
h-index

34
g-index

34
ext. papers

2,818
ext. citations

3.6
avg, IF

4.51
L-index

#	Paper	IF	Citations
34	Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 747-747	2.2	
33	Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model. <i>Biometrical Journal</i> , 2017 , 59, 1277-1300	1.5	20
32	Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. <i>Prostate</i> , 2017 , 77, 479-488	4.2	29
31	Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up. <i>Human Pathology</i> , 2016 , 55, 1-10	3.7	15
30	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. <i>Journal of Urology</i> , 2015 , 194, 790-8	2.5	67
29	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. <i>Cancer Research</i> , 2015 , 75, 5155-66	10.1	48
28	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015 , 116, 179-84	5.3	46
27	Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 293-293	2.2	4
26	Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014 , 110, 291-7	5.3	34
25	Cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219): Evaluation of bone metastasis microenvironment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16015-e16015	2.2	1
24	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16038-e16038	2.2	1
23	Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5019-5019	2.2	2
22	Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 546-53	4	28
21	The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer. <i>Prostate</i> , 2013 , 73, 1776-85	4.2	15
20	Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 84-84	2.2	
19	Investigation of a novel irreversible pan-HER inhibitor combined with chemotherapy in bladder cancer models.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4545-4545	2.2	
18	A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5094-TPS5094	2.2	

17	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. <i>Investigational New Drugs</i> , 2012 , 30, 249-57	4.3	57
16	Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012 , 30, 749-57	4.3	66
15	Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. <i>World Journal of Surgery</i> , 2012 , 36, 1509-16	3.3	66
14	Automated Area Calculation of Histopathologic Features Using SIVQ. <i>Analytical Cellular Pathology</i> , 2011 , 34, 265-275	3.4	8
13	A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. <i>Surgery</i> , 2011 , 150, 1178-85	3.6	28
12	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011 , 29, 1432-40	4.3	44
11	Patterns of hematuria referral to urologists: does a gender disparity exist?. <i>Urology</i> , 2008 , 72, 498-502; discussion 502-3	1.6	109
10	Understanding differences between high and low volume hospitals for radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 260-5	2.8	13
9	Hospital characteristics and use of innovative surgical therapies among patients with kidney cancer. <i>Medical Care</i> , 2008 , 46, 372-9	3.1	27
8	Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. <i>Cancer</i> , 2007 , 109, 1763-8	6.4	205
7	Volume-based referral for cancer surgery: informing the debate. <i>Journal of Clinical Oncology</i> , 2007 , 25, 91-6	2.2	112
6	Response: Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 570-571	9.7	8
5	Rising incidence of small renal masses: a need to reassess treatment effect. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1331-4	9.7	874
4	Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. <i>Cancer Research</i> , 2006 , 66, 385-92	10.1	111
3	Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. <i>Cancer Research</i> , 2006 , 66, 11897-906	10.1	83
2	Partial nephrectomy for small renal masses: an emerging quality of care concern?. <i>Journal of Urology</i> , 2006 , 175, 853-7; discussion 858	2.5	274
1	Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. <i>Journal of Urology</i> , 2006 , 175, 1262-7; discussion 1267	2.5	139